tiprankstipranks
Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat
PremiumPress ReleasesSagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat
2M ago
Sagimet Biosciences appoints Tim Walbert, Paul Hoelscher to board of directors
PremiumThe Fly
Sagimet Biosciences appoints Tim Walbert, Paul Hoelscher to board of directors
2M ago
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
PremiumPress Releases
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
2M ago
Sagimet Biosciences reports 2023 EPS ($2.66), consensus ($19.82)
PremiumThe FlySagimet Biosciences reports 2023 EPS ($2.66), consensus ($19.82)
2M ago
Sagimet Biosciences initiated with an Outperform at Leerink
PremiumThe Fly
Sagimet Biosciences initiated with an Outperform at Leerink
2M ago
Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
PremiumPress Releases
Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
2M ago
Sagimet Biosciences 9M share Secondary priced at $12.50
PremiumThe FlySagimet Biosciences 9M share Secondary priced at $12.50
4M ago
Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock
PremiumPress Releases
Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock
4M ago
Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock
PremiumPress Releases
Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100